TRVI — Trevi Therapeutics, Inc.

Trevi Therapeutics (TRVI) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Trevi ended Q1 2026 with approximately $172 million in cash, cash equivalents, and marketable securities.
• Recent Offering: The company completed a $162 million underwritten common stock offering in April 2026, which was well-received and extended the cash runway into 2030.
• Funding Plans: The cash resources will support ongoing clinical trials, including those for IPF-related chronic cough and refractory chronic cough (RCC).

2. Strategic Updates and Business Highlights

• FDA Alignment: Following a positive meeting with the FDA, Trevi has finalized protocols for Phase III trials related to IPF-related chronic cough and plans to initiate the first study this quarter.
• Non-IPF-ILD Program: The company intends to submit a protocol for a Phase II/III study for non-IPF interstitial lung disease-related chronic cough, with initiation expected in the second half of 2026.
• Refractory Chronic Cough Trials: A Phase IIb dose-ranging trial for RCC is set to begin this quarter, with a sample size reestimation (SSRE) expected by Q4 2026.
• Intellectual Property: Trevi secured a core method of treatment patent for IPF-related chronic cough in Europe, extending protection through 2039, with additional applications aimed at extending coverage to 2046.

3. Forward Guidance and Outlook

• Clinical Trial Timeline: Trevi anticipates initiating two pivotal studies for chronic cough this year and expects to report top-line data from the Phase IIb RCC trial in 2027.
• Investor Engagement: The company is hosting an Investor and Analyst Day to provide detailed timelines and insights into upcoming clinical trials and market research.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: The upcoming readout of a competitor's P2X3 antagonist could impact Trevi's market positioning in RCC. If results are strong, it may affect enrollment and competitive dynamics.
• Placebo Response: There are concerns regarding potential high placebo responses in RCC trials, which could complicate data interpretation and trial outcomes.
• Resource Allocation: Managing multiple clinical programs with a small team poses challenges, though management expressed confidence in their capabilities and recent hiring efforts to scale operations.

5. Notable Q&A Insights

• FDA Meeting Goals: The upcoming FDA meeting aims to discuss the Phase IIb/III protocol for non-IPF-ILD chronic cough, focusing on patient population and dose selection strategies.
• Competitive Positioning: Management believes that even if competitors succeed, Trevi's differentiated mechanism of action and existing data will support its position in the market.
• Dyspnea as a Metric: Dyspnea is a significant quality of life metric for patients, and its modulation could enhance the value proposition of Trevi's therapies.
• Enrollment Strategy: Trevi plans to include patients with prior P2X3 antagonist experience in the RCC trial, provided they meet eligibility criteria, reflecting a broader approach to patient selection.

Overall, Trevi Therapeutics is positioned for significant clinical advancements in 2026, with a strong cash position and strategic initiatives aimed at addressing chronic cough in various patient populations, despite facing competitive and operational challenges.